News

The center is said to be the ninth Solis facility in North Central Texas and expands the company’s services into this rapidly growing area. Brad Hummel, CEO of

Biotech company Amgen spent approximately $2.9 million on lobbying on the implementation of the Medicare drug benefit for seniors, reforming the US patent system and also to prevent

Mr Scibetta brings more than 20 years of financial leadership experience in private and public companies as well as investment banking to Pacira. Most recently he has been

Mr Prasad has spent more than 25 years in US and European leadership and management roles at such companies as Genentech, Chiron Vaccines, Medimmune and Genzyme. Most recently,

This investment will be used to augment Chemizon Beijing’s integrated discovery platform by adding capabilities in the area of biology and computational chemistry. Anthony Piscopio, president, CEO and

The final portion of the biologics license application (BLA) submission includes all of the clinical safety and efficacy data generated from studies of ATryn, including the pivotal study

Under the terms of the agreement, Roche will provide a $10 million upfront payment. In the event a development candidate is identified, Roche will assume development responsibility, and

The panel of markers being acquired by Miraculins has shown evidence of its ability to diagnose the disease in its earliest stages. According to Miraculins, a reliable test

The primary objective of the Phase I/II, dose escalation study is to determine the safety, maximum tolerated dose and objective response rate of GRN163L when administered intravenously in